Maravai LifeSciences Holdings Inc（MRVI）財務資料MRVIMaravai LifeSciences Holdings Inc

Maravai LifeSciences Holdings Inc (MRVI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Nucleic Acid Production, accounting for 67.4% of total sales, equivalent to $34.67M. Another important revenue stream is Biologics Safety Testing. Understanding this composition is critical for investors evaluating how MRVI navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Maravai LifeSciences Holdings Inc maintains a gross margin of 40.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25.78%, while the net margin is -42.05%. These profitability ratios, combined with a Return on Equity (ROE) of -32.90%, provide a clear picture of how effectively MRVI converts its operational activities into shareholder value.

In the context of the broader market, MRVI competes directly with industry leaders such as XERS and ADRX. With a market capitalization of $1.84B, it holds a significant position in the sector. When comparing efficiency, MRVI's gross margin of 40.14% stands against XERS's 83.47% and ADRX's N/A. Such benchmarking helps identify whether Maravai LifeSciences Holdings Inc is trading at a premium or discount relative to its financial performance.

Maravai's gross margin improved to 40.14% in Q2 2026, up from 16.39% in Q2 2025, indicating better cost management and revenue generation. The company reported a net income loss of only $12.42 million in Q2 2026, a significant improvement compared to losses exceeding $39 million in previous quarters.